The blog
Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.
30 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · tga · sport-integrity
A 2026 scoping review screened 1,772 records on TB-500 and thymosin beta-4. Just one study tested TB-500 itself. Plus the Australian legal status, explained.
Read more →27 September 2026 · bpc-157 · tb-500 · research · australia · tendon
A 2026 rat study tested BPC-157, TB-500 and the combo on Achilles repair. The stack beat neither alone. What that means for BPC-157 research and Australia.
Read more →27 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · australia · regulation
What is TB-500? A 7-residue fragment of thymosin beta-4, not the same molecule. TB-500 research, the human evidence gap, and is TB-500 legal in Australia.
Read more →24 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · clinical-trials · australia
TB-500 research explained: thymosin beta-4's only late-stage human programme is an eye drop, and it just missed again. Plus is TB-500 legal in Australia?
Read more →21 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · australia · clinical-trials
A 2025 Cardiovascular Research trial tested injected thymosin beta-4 in 96 heart attack patients. What the null result means for TB-500 research and Australia.
Read more →19 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · tga-scheduling
What is TB-500? Most TB-500 research is actually thymosin beta-4 research - a 43-amino-acid parent, not the 7-residue fragment. Plus its Australian legal status.
Read more →16 September 2026 · tb-500 · thymosin-beta-4 · peptide-research · tga · clinical-trials
TB-500 research explained: thymosin beta-4's only human efficacy trials are eye drops with a mixed Phase 3 record, plus its Appendix D status in Australia.
Read more →13 September 2026 · tb-500 · thymosin-beta-4 · peptides · clinical-trials · australia
Thymosin beta-4's first randomised heart attack trial missed its overall endpoint. What that means for TB-500 research and its legal status in Australia.
Read more →10 September 2026 · tb-500 · thymosin-beta-4 · peptide-regulation · tga · fda
Is TB-500 legal in Australia? What the vial contains often isn't thymosin beta-4 - and a July 2026 FDA panel vote made the distinction impossible to ignore.
Read more →28 August 2026 · tb-500 · thymosin-beta-4 · peptides · australia · research
TB-500 is sold for injury recovery, but thymosin beta-4's only late-stage human trials are eye drops. What the 2026 evidence and Australian rules say.
Read more →27 August 2026 · tb-500 · peptides · recovery · research
TB-500 is sold as a recovery peptide, but the thymosin beta-4 evidence is mostly animal research. What the science, WADA and the TGA actually say.
Read more →Stay informed
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.